(Q43563785)

24 November 2017

title

Comparative efficacy of new investigational agents against Helicobacter pylori (English)

1 reference

24 November 2017

1 reference

6

Graham DY

1 reference

24 November 2017

Osato MS

1

1 reference

24 November 2017

Reddy SG

2

1 reference

24 November 2017

Piergies AA

3

1 reference

24 November 2017

Bochenek WJ

4

1 reference

24 November 2017

Testa RT

5

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

Alimentary Pharmacology & Therapeutics

24 November 2017

published in

1 reference

24 November 2017

volume

15

1 reference

24 November 2017

issue

4

1 reference

24 November 2017

page(s)

487-492

1 reference

Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years.

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

Macrolide antibiotics in paediatric infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

In vitro activities of two new glycylcyclines, N,N-dimethylglycylamido derivatives of minocycline and 6-demethyl-6-deoxytetracycline, against 339 strains of anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

Antibiotic resistance in Helicobacter pylori: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

Activity of cefixime against Helicobacter pylori and affinities for the penicillin-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

Reduction of gastric ulcer recurrence after suppression of Helicobacter pylori by cefixime

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00957.X

10.1046/J.1365-2036.2001.00957.X

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference